State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa 999078, Macao SAR, China.
Department of Chemistry, Hong Kong Baptist University, Kowloon Tong 999077, Hong Kong, China.
Drug Discov Today. 2020 Sep;25(9):1754-1761. doi: 10.1016/j.drudis.2020.07.010. Epub 2020 Jul 15.
S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metabolism by physical interactions with other molecules. Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors. Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction. Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors. In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico analysis for drug discovery.
S100 钙结合蛋白 B(S100B)在各种恶性肿瘤中过度表达,通过与其他分子的物理相互作用来调节癌细胞的增殖和代谢。干扰 S100B-效应蛋白相互作用是治疗恶性肿瘤的一种潜在策略。尽管已经通过虚拟筛选(VS)发现了一些 S100B 抑制剂,但大多数都针对 S100B-p53 相互作用。因此,有发现其他 S100B-效应蛋白相互作用调节剂用于恶性肿瘤的空间。在这篇综述中,我们提供了使用 VS 发现 S100B-效应蛋白相互作用抑制剂的概述,并讨论了有前途的 S100B-效应蛋白相互作用靶标,允许进行药物发现的计算机分析。